Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 11:8:55-60.
doi: 10.2174/1874192401408010055. eCollection 2014.

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study

Panagiotis Anagnostis  1 , Fotini Adamidou  2 , Aristidis Slavakis  3 , Stergios A Polyzos  2 , Despina Selalmatzidou  2 , Athanasios Panagiotou  2 , Vasilios G Athyros  4 , Asterios Karagiannis  4 , Marina Kita  2
Affiliations

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study

Panagiotis Anagnostis et al. Open Cardiovasc Med J. .

Abstract

Aims: Low 25-hydroxy-vitamin D [25(ΟΗ)D] levels have been associated with increased risk for cardiovascular disease. Conflicting data exist regarding the effect of statins on [25(OH)D] levels. The aim of this study was to compare the effect of atorvastatin and rosuvastatin on 25(OH)D levels in non-diabetic patients with dyslipidaemia.

Methods: This was a prospective randomized open-label study. Patients were assigned to atorvastatin 20 mg⁄day (n=28, age: 56.1±2.2 years, 22 females) or rosuvastatin 10 mg⁄day (n=24, age: 57.4±1.9 years, 20 females). Total cholesterol (TC), low- (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting plasma glucose, insulin, glycosylated haemoglobin A1c (HbA1c) and high sensitivity C-reactive protein (hsCRP) levels were measured, and homeostatic model of assessment insulin resistance (HOMA-IR) was calculated at baseline and 12 weeks post-treatment.

Results: There were no within or between group significant differences in 25(OH)D levels (atorvastatin: 21.7±1.9 ng/ml at baseline and 23.5±2.3 ng/ml at week 12; rosuvastatin: 25.3±1.8 and 27.0±2.4 ng/ml, respectively; p=0.172 and p=0.306 for between groups, respectively). Both statins significantly reduced TC, TG and LDL-C levels, with a greater LDL-C reduction being observed by rosuvastatin.

Conclusion: Atorvastatin and rosuvastatin did not significantly affect 25(OH)D levels in this study.

Keywords: 25(OH)D; atorvastatin; glucose homeostasis; rosuvastatin; systemic inflammation; vitamin D..

PubMed Disclaimer

References

    1. Baigent C, Keech A, Kearney PM , et al. Cholesterol Treatment Trialists' (CTT) Collaborators.Efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 9056 participants in 14 randomised trials of statins. Lancet . 2005;366: 1267–78. - PubMed
    1. Athyros VG, Kakafika AI, Papageorgiou AA , et al. Effects of statin treatment in men and women with stable coronary heart disease a subgroup analysis of the GREACE Study. Curr Med Res Opin. 2008;24: 1593–9. - PubMed
    1. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des. 2009;15: 479–89. - PubMed
    1. Ott C, Raff U, Schneider MP, Titze SI, Schmieder RE. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. . Clin Res Cardiol. 2013;102: 299–304. - PubMed
    1. Yavuz B, Ertugrul DT, Cil H , et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment a novel pleiotropic effect of statins. Cardiovasc Drugs Ther. 2009;23: 295–9. - PubMed

LinkOut - more resources